|
Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial. |
|
|
Honoraria - AstraZeneca; Janssen-Cilag; PharmaMar; Roche Pharma AG |
Consulting or Advisory Role - Amgen; Roche Pharma AG |
Research Funding - PharmaMar (Inst); Roche Pharma AG (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Clovis Oncology; Merck Sharp & Dohme; PharmaMar; Roche Pharma AG |
Consulting or Advisory Role - Amgen; Clovis Oncology; Merck Sharp & Dohme; PharmaMar; Roche Pharma AG |
|
|
Honoraria - AstraZeneca; Roche Pharma AG |
Consulting or Advisory Role - AstraZeneca; Roche Pharma AG |
Research Funding - AstraZeneca (Inst); Janssen-Cilag (Inst); Roche Pharma AG (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; PharmaMar; Roche Pharma AG |
Consulting or Advisory Role - Amgen; Roche Pharma AG |
|
|
No Relationships to Disclose |